Literature DB >> 14515991

Phosphatidylinositol-3,5-Bisphosphate is a potent and selective inhibitor of acid sphingomyelinase.

Melanie Kölzer1, Christoph Arenz, Klaus Ferlinz, Norbert Werth, Heike Schulze, Ralf Klingenstein, Konrad Sandhoff.   

Abstract

Acid sphingomyelinase (A-SMase, EC 3.1.4.12) catalyzes the lysosomal degradation of sphingomyelin to phosphorylcholine and ceramide. Inherited deficiencies of acid sphingomyelinase activity result in various clinical forms of Niemann-Pick disease, which are characterised by massive lysosomal accumulation of sphingomyelin. Sphingomyelin hydrolysis by both, acid sphingomyelinase and membrane-associated neutral sphingomyelinase, plays also an important role in cellular signaling systems regulating proliferation, apoptosis and differentiation. Here, we present a potent and selective novel inhibitor of A-SMase, L-alpha-phosphatidyl-D-myo-inositol-3,5-bisphosphate (PtdIns3,5P2), a naturally occurring substance detected in mammalian, plant and yeast cells. The inhibition constant Ki for the new A-SMase inhibitor PtdIns3,5P2 is 0.53 microM as determined in a micellar assay system with radiolabeled sphingomyelin as substrate and recombinant human A-SMase purified from insect cells. Even at concentrations of up to 50 microM, PtdIns3,5P2 neither decreased plasma membrane-associated, magnesium-dependent neutral sphingomyelinase activity, nor was it an inhibitor of the lysosomal hydrolases beta-hexosaminidase A and acid ceramidase. Other phosphoinositides tested had no or a much weaker effect on acid sphingomyelinase. Different inositol-bisphosphates were studied to elucidate structure-activity relationships for A-SMase inhibition. Our investigations provide an insight into the structural features required for selective, efficient inhibition of acid sphingomyelinase and may also be used as starting point for the development of new potent A-SMase inhibitors optimised for diverse applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14515991     DOI: 10.1515/BC.2003.144

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  16 in total

Review 1.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

Review 2.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 3.  Lipid raft redox signaling: molecular mechanisms in health and disease.

Authors:  Si Jin; Fan Zhou; Foad Katirai; Pin-Lan Li
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

Review 4.  Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network.

Authors:  Jan Skácel; Barbara S Slusher; Takashi Tsukamoto
Journal:  J Med Chem       Date:  2021-01-04       Impact factor: 7.446

5.  The role of sphingolipids and ceramide in pulmonary inflammation in cystic fibrosis.

Authors:  Katrin Anne Becker; Joachim Riethmüller; Yang Zhang; Erich Gulbins
Journal:  Open Respir Med J       Date:  2010-03-30

Review 6.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

7.  Dementia in a child with myotubular myopathy.

Authors:  Heather J McCrea; Christine Kretz; Jocelyn Laporte; Laura R Ment
Journal:  Pediatr Neurol       Date:  2009-06       Impact factor: 3.372

Review 8.  The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease.

Authors:  E H Schuchman
Journal:  J Inherit Metab Dis       Date:  2007-07-12       Impact factor: 4.982

9.  Identification of novel functional inhibitors of acid sphingomyelinase.

Authors:  Johannes Kornhuber; Markus Muehlbacher; Stefan Trapp; Stefanie Pechmann; Astrid Friedl; Martin Reichel; Christiane Mühle; Lothar Terfloth; Teja W Groemer; Gudrun M Spitzer; Klaus R Liedl; Erich Gulbins; Philipp Tripal
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

Review 10.  Pathological changes in the central nervous system following exposure to ionizing radiation.

Authors:  S Bálentová; M Adamkov
Journal:  Physiol Res       Date:  2020-05-29       Impact factor: 1.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.